Emily F Conant1, William E Barlow2, Sally D Herschorn3,4, Donald L Weaver4,5, Elisabeth F Beaber6, Anna N A Tosteson7,8,9, Jennifer S Haas10, Kathryn P Lowry11, Natasha K Stout12, Amy Trentham-Dietz13, Roberta M diFlorio-Alexander14, Christopher I Li15, Mitchell D Schnall1, Tracy Onega9,16,17,18, Brian L Sprague3,4,19. 1. Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 2. Cancer Research and Biostatistics, Seattle, Washington. 3. Department of Radiology, University of Vermont, Burlington. 4. University of Vermont Cancer Center, University of Vermont, Burlington. 5. Department of Pathology, University of Vermont, Burlington. 6. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. 7. Department of Community & Family Medicine, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. 8. The Dartmouth Institute for Health Policy & Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. 9. Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. 10. Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, Massachusetts. 11. Department of Radiology, University of Washington, Seattle. 12. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts. 13. Department of Population Health Sciences and Carbone Cancer Center, University of Wisconsin, Madison. 14. Department of Radiology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire. 15. Translational Research Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 16. Dartmouth Institute for Health Policy and Clinical Practice and Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. 17. Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. 18. Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. 19. Department of Surgery, University of Vermont, Burlington.
Abstract
IMPORTANCE: Breast cancer screening examinations using digital breast tomosynthesis (DBT) has been shown to be associated with decreased false-positive test results and increased breast cancer detection compared with digital mammography (DM). Little is known regarding the size and stage of breast cancer types detected and their association with age and breast density. OBJECTIVE: To determine whether screening examinations using DBT detect breast cancers that are associated with an improved prognosis and to compare the detection rates by patient age and breast density. DESIGN, SETTING, AND PARTICIPANTS: This retrospective analysis of prospective cohort data from 3 research centers in the Population-based Research Optimizing Screening Through Personalized Regimens (PROSPR) consortium included data of women aged 40 to 74 years who underwent screening examinations using DM and DBT from January 1, 2011, through September 30, 2014. Statistical analysis was performed from November 8, 2017, to August 14, 2018. EXPOSURES: Use of DBT as a supplement to DM at breast cancer screening examination. MAIN OUTCOMES AND MEASURES: Recall rate, cancer detection rate, positive predictive value, biopsy rate, and distribution of invasive cancer subtypes. RESULTS: Among 96 269 women (mean [SD] patient age for all examinations, 55.9 [9.0] years), patient age was 56.4 (9.0) years for DM and 54.6 (8.9) years for DBT. Of 180 340 breast cancer screening examinations, 129 369 examinations (71.7%) used DM and 50 971 examinations (28.3%) used DBT. Screening examination with DBT (73 of 99 women [73.7%]) was associated with the detection of smaller, more often node-negative, HER2-negative, invasive cancers compared with DM (276 of 422 women [65.4%]). Screening examination with DBT was also associated with lower recall (odds ratio, 0.64; 95% CI, 0.57-0.72; P < .001) and higher cancer detection (odds ratio, 1.41; 95% CI, 1.05-1.89; P = .02) compared with DM for all age groups even when stratified by breast density. The largest increase in cancer detection rate and the greatest shift toward smaller, node-negative invasive cancers detected with DBT was for women aged 40 to 49 years. For women aged 40 to 49 years with nondense breasts, the cancer detection rate for examinations using DBT was 1.70 per 1000 women higher compared with the rate using DM; for women with dense breasts, the cancer detection rate was 2.27 per 1000 women higher for DBT. For these younger women, screening with DBT was associated with only 7 of 28 breast cancers (25.0%) categorized as poor prognosis compared with 19 of 47 breast cancers (40.4%) when screening with DM. CONCLUSIONS AND RELEVANCE: The findings suggest that screening with DBT is associated with increased specificity and an increased proportion of breast cancers detected with better prognosis compared with DM. In the subgroup of women aged 40 to 49 years, routine DBT screening may have a favorable risk-benefit ratio.
IMPORTANCE: Breast cancer screening examinations using digital breast tomosynthesis (DBT) has been shown to be associated with decreased false-positive test results and increased breast cancer detection compared with digital mammography (DM). Little is known regarding the size and stage of breast cancer types detected and their association with age and breast density. OBJECTIVE: To determine whether screening examinations using DBT detect breast cancers that are associated with an improved prognosis and to compare the detection rates by patient age and breast density. DESIGN, SETTING, AND PARTICIPANTS: This retrospective analysis of prospective cohort data from 3 research centers in the Population-based Research Optimizing Screening Through Personalized Regimens (PROSPR) consortium included data of women aged 40 to 74 years who underwent screening examinations using DM and DBT from January 1, 2011, through September 30, 2014. Statistical analysis was performed from November 8, 2017, to August 14, 2018. EXPOSURES: Use of DBT as a supplement to DM at breast cancer screening examination. MAIN OUTCOMES AND MEASURES: Recall rate, cancer detection rate, positive predictive value, biopsy rate, and distribution of invasive cancer subtypes. RESULTS: Among 96 269 women (mean [SD] patient age for all examinations, 55.9 [9.0] years), patient age was 56.4 (9.0) years for DM and 54.6 (8.9) years for DBT. Of 180 340 breast cancer screening examinations, 129 369 examinations (71.7%) used DM and 50 971 examinations (28.3%) used DBT. Screening examination with DBT (73 of 99 women [73.7%]) was associated with the detection of smaller, more often node-negative, HER2-negative, invasive cancers compared with DM (276 of 422 women [65.4%]). Screening examination with DBT was also associated with lower recall (odds ratio, 0.64; 95% CI, 0.57-0.72; P < .001) and higher cancer detection (odds ratio, 1.41; 95% CI, 1.05-1.89; P = .02) compared with DM for all age groups even when stratified by breast density. The largest increase in cancer detection rate and the greatest shift toward smaller, node-negative invasive cancers detected with DBT was for women aged 40 to 49 years. For women aged 40 to 49 years with nondense breasts, the cancer detection rate for examinations using DBT was 1.70 per 1000 women higher compared with the rate using DM; for women with dense breasts, the cancer detection rate was 2.27 per 1000 women higher for DBT. For these younger women, screening with DBT was associated with only 7 of 28 breast cancers (25.0%) categorized as poor prognosis compared with 19 of 47 breast cancers (40.4%) when screening with DM. CONCLUSIONS AND RELEVANCE: The findings suggest that screening with DBT is associated with increased specificity and an increased proportion of breast cancers detected with better prognosis compared with DM. In the subgroup of women aged 40 to 49 years, routine DBT screening may have a favorable risk-benefit ratio.
Authors: Stephen L Rose; Andra L Tidwell; Louis J Bujnoch; Anne C Kushwaha; Amy S Nordmann; Russell Sexton Journal: AJR Am J Roentgenol Date: 2013-06 Impact factor: 3.959
Authors: Anne Marie McCarthy; Despina Kontos; Marie Synnestvedt; Kay See Tan; Daniel F Heitjan; Mitchell Schnall; Emily F Conant Journal: J Natl Cancer Inst Date: 2014-10-13 Impact factor: 13.506
Authors: Melissa A Durand; Brian M Haas; Xiaopan Yao; Jaime L Geisel; Madhavi Raghu; Regina J Hooley; Laura J Horvath; Liane E Philpotts Journal: Radiology Date: 2014-09-01 Impact factor: 11.105
Authors: Jin You Kim; Hyun Jung Kang; Jong Ki Shin; Nam Kyung Lee; You Seon Song; Kyung Jin Nam; Ki Seok Choo Journal: AJR Am J Roentgenol Date: 2017-08-23 Impact factor: 3.959
Authors: Elizabeth A Rafferty; Stephen L Rose; Dave P Miller; Melissa A Durand; Emily F Conant; Debra S Copit; Sarah M Friedewald; Donna M Plecha; Ingrid L Ott; Mary K Hayes; Kara L Carlson; Thomas M Cink; Lora D Barke; Linda N Greer; Loren T Niklason Journal: Breast Cancer Res Treat Date: 2017-05-18 Impact factor: 4.872
Authors: Elizabeth S McDonald; Andrew Oustimov; Susan P Weinstein; Marie B Synnestvedt; Mitchell Schnall; Emily F Conant Journal: JAMA Oncol Date: 2016-06-01 Impact factor: 31.777
Authors: Sarah M Friedewald; Elizabeth A Rafferty; Stephen L Rose; Melissa A Durand; Donna M Plecha; Julianne S Greenberg; Mary K Hayes; Debra S Copit; Kara L Carlson; Thomas M Cink; Lora D Barke; Linda N Greer; Dave P Miller; Emily F Conant Journal: JAMA Date: 2014-06-25 Impact factor: 56.272
Authors: Elizabeth S McDonald; Anne Marie McCarthy; Amana L Akhtar; Marie B Synnestvedt; Mitchell Schnall; Emily F Conant Journal: AJR Am J Roentgenol Date: 2015-11 Impact factor: 3.959
Authors: Jennifer M Yeh; Kathryn P Lowry; Clyde B Schechter; Lisa R Diller; Oguzhan Alagoz; Gregory T Armstrong; John M Hampton; Wendy Leisenring; Qi Liu; Jeanne S Mandelblatt; Diana L Miglioretti; Chaya S Moskowitz; Kevin C Oeffinger; Amy Trentham-Dietz; Natasha K Stout Journal: Ann Intern Med Date: 2020-07-07 Impact factor: 25.391
Authors: Janice S Sung; Lizza Lebron; Delia Keating; Donna D'Alessio; Christopher E Comstock; Carol H Lee; Malcolm C Pike; Miranda Ayhan; Chaya S Moskowitz; Elizabeth A Morris; Maxine S Jochelson Journal: Radiology Date: 2019-08-27 Impact factor: 11.105
Authors: Emily F Conant; Samantha P Zuckerman; Elizabeth S McDonald; Susan P Weinstein; Katrina E Korhonen; Julia A Birnbaum; Jennifer D Tobey; Mitchell D Schnall; Rebecca A Hubbard Journal: Radiology Date: 2020-03-10 Impact factor: 11.105
Authors: Samantha P Zuckerman; Brian L Sprague; Donald L Weaver; Sally D Herschorn; Emily F Conant Journal: Radiology Date: 2020-10-13 Impact factor: 11.105